• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy
Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy, Published online: 15 April 2019; doi:10.1038/s41391-019-0150-5Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy
Source: Prostate Cancer and Prostatic Diseases - April 14, 2019 Category: Urology & Nephrology Authors: Rishi Deka Daniel R. Simpson Matthew S. Panizzon Richard L. Hauger Paul Riviere Vinit Nalawade Rana McKay James D. Murphy Brent S. Rose Source Type: research

Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men
ConclusionsDigital rectal examination is a modestly accurate tool for measuring prostate volume. While DRE posterior surface area represents a statistically significant predictor of nocturia, the magnitude of effect suggests it has limited clinical utility for assessing this condition, particularly in the presence of cardiovascular risk factors.
Source: BJU International - August 22, 2016 Category: Urology & Nephrology Authors: Benjamin V. Stone, Jonathan Shoag, Joshua A. Halpern, Sameer Mittal, Patrick Lewicki, David M. Golombos, Dina Bedretdinova, Bilal Chughtai, Christopher E. Barbieri, Richard K. Lee Tags: Original Article Source Type: research

Prostate size, nocturia, and the digital rectal exam: a cohort study of 30,500 men
ConclusionsDRE is a modestly accurate tool for measuring prostate volume. While DRE posterior surface area represents a statistically significant predictor of nocturia, the magnitude of effect suggests it has limited clinical utility for assessing this condition, particularly in the presence of cardiovascular risk factors.This article is protected by copyright. All rights reserved.
Source: BJU International - July 31, 2016 Category: Urology & Nephrology Authors: Benjamin V. Stone, Jonathan Shoag, Joshua A. Halpern, Sameer Mittal, Patrick Lewicki, David M. Golombos, Dina Bedretdinova, Bilal Chughtai, Christopher E. Barbieri, Richard K. Lee Tags: Original Article Source Type: research

Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective
Abstract Androgen deprivation therapy (ADT) plays an important role in managing prostate cancer. However, ADT may result in major cardiovascular events and potentially lead to fatal consequences. Cardiovascular disease is the leading cause of mortality and it is a very important health condition to look into. Asians and Caucasians differ both physiologically and genetically, and they may have display different cardiovascular profiles. In this article, we reviewed the literature focusing on the cardiovascular risk after ADT for prostate cancer in the Asian population. We would discuss about the pathogenesis of ADT ...
Source: International Urology and Nephrology - June 1, 2016 Category: Urology & Nephrology Source Type: research

Pd50-03 cardiovascular events and prostate cancer diagnoses in men treated with testosterone replacement therapy
The U.S. Food and Drug Administration recently issued a caution that testosterone replacement therapy (TRT) may increase the risk of heart attack and stroke. This was based primarily on studies that had short follow-up and limited duration of treatment. We sought to determine the association of the long-term use of TRT and rates of cardiovascular events, prostate cancer, and overall mortality.
Source: The Journal of Urology - March 28, 2016 Category: Urology & Nephrology Authors: Christopher Wallis, Kirk Lo, Yuna Lee, Yonah Krakowsky, Alaina Garbens, Raj Satkunasivam, Sender Herschorn, Ronald Kodama, Patrick Cheung, Steven Narod, Robert Nam Tags: Sexual Function/Dysfunction: Medical, Hormonal & Non-surgical Therapy II Source Type: research

No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men
This study included 1278 patients with prostate cancer in the study group and 1278 subjects without prostate cancer in the comparison group. Each patient was individually tracked for a 3‐year period to identify those who had subsequently received a diagnosis of CHD. The results showed that the incidence rate of CHD during the 3‐year follow‐up period was 4.69 (95% CI: 2.99–5.48) per 100 person‐years and 2.67 (95% CI: 2.15–3.27) per 100 person‐years for the study and comparison cohort, respectively. The Cox proportional hazard regression showed that the hazard ratio for CHD during the 3‐year follow‐up perio...
Source: Andrology - December 29, 2015 Category: Urology & Nephrology Authors: L. H. Wang, C. K. Liu, C. H. Chen, L. T. Kao, H. C. Lin, C. Y. Huang Tags: Original Article Source Type: research

Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis
Conclusions Observational data show a consistent positive association between ADT and the risk of CVD. This finding supports the need for future randomised trials of PCa patients that include older patients and men with multiple comorbidities to better reflect the general population. Patient summary We investigated all the available data from observational studies on hormonal treatment for prostate cancer and its possible cardiovascular adverse effects. We found consistent evidence that this treatment may increase the risk of cardiovascular disease. Using observational data, our meta-analysis showed consistent positive as...
Source: European Urology - August 5, 2015 Category: Urology & Nephrology Source Type: research

Mp46-13 nitrone-based therapy for treatment of a murine model of human castration resistant prostate cancer
OKN-007 is a nitrone-based agent developed as an anti-oxidant to reduce stroke-related complications. However, despite making it through Phase-III trials, this nontoxic agent was not clinically effective enough to go to market. We have repurposed OKN-007 as an anticancer agent and are testing it against a murine model of human castrate resistant prostate cancer (CRPC).
Source: The Journal of Urology - April 1, 2015 Category: Urology & Nephrology Authors: Joel Slaton, Carole Davis, Nataliya Smith, Debbie Saunders, Rober Hurst, Rheal Towner Tags: Prostate Cancer: Basic Research II Source Type: research

Risk of acute myocardial infarction after androgen‐deprivation therapy for prostate cancer in a Chinese population
ConclusionsThere was increased risk of AMI after ADT for prostate cancer in a Chinese population. Hyperlipidaemia and poor ECOG PS were also significant risk factors for developing AMI. The risk of AMI should be considered when deciding on ADT, especially in patients with history of hyperlipidaemia and relatively poor ECOG PS.
Source: BJU International - March 7, 2015 Category: Urology & Nephrology Authors: Jeremy Y.C. Teoh, Samson Y.S. Chan, Peter K.F. Chiu, Darren M.C. Poon, Ho‐Yuen Cheung, Simon S.M. Hou, Chi‐Fai Ng Tags: Original Article Source Type: research

Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer.
In conclusion, SC was associated with increased risk of cardiovascular thrombotic events when compared to GnRHa. This is an important aspect to consider while deciding on the method of androgen deprivation therapy, especially in elderly men with known history of hyperlipidemia. PMID: 25578930 [PubMed - as supplied by publisher]
Source: Asian Journal of Andrology - December 23, 2014 Category: Urology & Nephrology Authors: Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS, Ng CF Tags: Asian J Androl Source Type: research

Risk of Acute Myocardial Infarction after Androgen Deprivation Therapy for Prostate Cancer in the Chinese Population
Conclusions‐ There was increased risk of AMI after ADT for prostate cancer in the Chinese population.‐ Hyperlipidemia and poor ECOG performance status were also significant risk factors for developing AMI.‐ The risk of AMI should be considered while deciding on ADT, especially in patients with history of hyperlipidemia and relatively poor ECOG performance status.Prostate cancer, androgen deprivation therapy, myocardial infarction, Asian population
Source: BJU International - October 18, 2014 Category: Urology & Nephrology Authors: Jeremy Yuen Chun Teoh, Samson Yun Sang Chan, Peter Ka Fung Chiu, Darren Ming Chun Poon, Ho Yuen Cheung, Simon See Ming Hou, Chi‐Fai Ng Tags: Urological Oncology Source Type: research